Clinicopathological and immunohistochemical features of lung invasive mucinous adenocarcinoma based on computed tomography findings

Figures & data

Figure 1 Computed tomography findings of lung invasive mucinous adenocarcinoma.

Notes: (A) Solid type, (B) bubbling type, and (C) pneumonic type.

Table 1 Clinical characteristics of patients based on computed tomography findings

Characteristics	Solid type	Bubbling type	Pneumonic type	P-value
Patients	10	9	10
Age (years)	70.9±12.4	71.3±7.7	73.6±4.7	0.458
Sex				0.975
Male	6	5	6
Female	4	4	4
Smoking history				0.645
Negative	4	5	6
Positive	6	4	4
Symptom				0.004
Negative	1	0	6
Positive	9	9	4
Tumor size (mm)	23.6±7.2	22.2±10.8	65.0±29.9	0.001
SUVmax	4.7±4.3 (8/10)	1.6±1.2 (7/9)	6.1±2.3 (9/10)	0.002

Note: Data presented as n, mean ± SD, or (n/N).

Abbreviation: SUVmax, maximal standardized uptake value.

Table 2 Pathological characteristics of patients based on computed tomography findings

Characteristics	Solid type	Bubbling type	Pneumonic type	P-value
Patients	10	9	10
Tumor size (mm)	21.8±6.5	23.8±11.4	59.7±17.8	0.001
Lymph node metastasis				0.996
Negative	9	8	9
Positive	1	1	1
Lymphatic invasion				0.352
Negative	8	9	8
Positive	2	0	2
Vascular invasion				0.617
Negative	9	9	9
Positive	1	0	1
Pleural involvement				0.152
Negative	7	9	9
Positive	3	0	1
Pathological stage				0.017
IA/IB	5/4	7/1	0/3
IIA/IIB	0/0	1/0	3/3
IIIA	1	0	1
TTF-1 expression				0.283
Negative	9	7	10
Positive	1	2	0
CK7 expression				0.316
Negative	0	1	0
Positive	10	8	10
CK20 expression				0.861
Negative	3	2	2
Positive	7	7	8
EGFR mutation				0.677
Negative	9	7	9
Positive	1	2	1

Note: Data presented as n, mean ± SD, or (n/N).

Abbreviations: CK, cytokeratin; EGFR, epidermal growth factor receptor; TTF-1, thyroid transcription factor-1.

Table 3 Prognosis of patients based on computed tomography findings

Characteristics	Solid type (n)	Bubbling type (n)	Pneumonic type (n)	P-value
Patients	10	9	10
Recurrence				0.004
Intrathoracic	1a	0	6
Extrathoracic	0	0	0
Intrathoracic recurrence
Lung	0	0	6
Dissemination	1a	0	1b
Lymph node	0	0	1c
Death
Lung cancer	1	0	2
Other cancer	0	1	0
Noncancer	0	0	0

Notes:

a Case of wedge resection due to compromised patient.

b Lung + pleural dissemination (n=1).

c Lung + mediastinal lymph node metastasis (n=1). raphy findings.

Figure 2 Kaplan–Meier recurrence-free survival curve based on computed tomography findings.

Figure 3 The immunohistochemical H-score for each marker expression profile based on the computed tomography findings.

Note: °Indicates outliers; *indicates extreme values.
Abbreviations: Cox-2, cyclooxygenase-2; ERCC1, excision repair cross-complementation group 1; H-score, histologic score; PD-L1, programmed cell death-1 ligand-1; RRM1, ribonucleotide reductase M1; SD, standard deviation; SPARC, secreted protein acidic and rich in cysteine; TS, thymidylate synthase.

Figure 4 Kaplan–Meier recurrence-free survival curve according to SPARC expression.

Notes: (A) Tumor tissue. (B) Stroma tissue.
Abbreviation: SPARC, secreted protein acidic and rich in cysteine.

Figure S1 Representative photomicrographs of biomarker expression.

Notes: Magnification ×200. (A) ERCC1; nuclear staining, mean H-score: 66, negative case score: 0, positive case score: 190. (B) RRM1; cytoplasmic staining, mean H-score: 178, negative case score: 0, positive case score: 260. (C) TS; cytoplasmic staining, mean H-score: 2.4, negative case score: 0, positive case score: 30. (D) Class III beta-tubulin, cytoplasmic staining, mean H-score: 126, negative case score: 10, positive case score: 280. (E) PD-L1, membrane staining, mean H-score: 4.8, negative case score: 0, positive case score: 50. (F) Cox-2; cytoplasmic staining, mean H-score: 181, negative case score: 60, positive case score: 270. (G) SPARC in tumor tissue; cytoplasmic staining, mean H-score: 32, negative case score: 0, positive case score: 90. (H) SPARC in stroma tissue; cytoplasmic staining, mean H-score:122, negative case score: 10, positive case score: 240.

Abbreviations: Cox-2, cyclooxygenase-2; ERCC1, excision repair cross-complementation group 1; H-score, histologic score; PD-L1, programmed cell death-1 ligand-1; RRM1, ribonucleotide reductase M1; SPARC, secreted protein acidic and rich in cysteine; TS, thymidylate synthase.

Table S1 Antibodies and conditions

Antibody	Clone	Duration	Localization	Source	References
Cox-2	CX-294	1:50	Cytoplasm	DAKO, Carpinteria, CA, USA	Edelman et al^Citation1
TTF-1	8G7G3/1	1:50	Nuclei	Abcam, Cambridge, MA, USA	Simsir et al^Citation2
CK7	SP52	1:100	Cytoplasm	Abcam	Simsir et al^Citation2
CK20	EPR1622Y	1:100	Cytoplasm	Abcam	Simsir et al^Citation2
ERCC1	8F1	1:100	Nuclei	Abcam	He et al^Citation3
RRM1	Polyclonal	1:50	Cytoplasm	Abcam	He et al^Citation3
TS	ATYMSMAB	1:500	Cytoplasm	Immuno-Biological Laboratories Co., Ltd., Fujioka-Shi, Japan	He et al^Citation3
Class III beta-tubulin	TUJ1	1:400	Cytoplasm	BioLegend, San Diego, CA, USA	Sève et al^Citation4
SPARC	Polyclonal	1:500	Cytoplasm	Atlas Antibodies AB, Bromma, Sweden	Hidalgo et al^Citation5
PD-L1	SP142	1:100	Cell membrane	Spring Bioscience, Pleasanton, CA, USA	Borghaei et al^Citation6

Abbreviations: CK, cytokeratin; Cox-2, cyclooxygenase-2; ERCC1, excision repair cross-complementation group 1; PD-L1, programmed cell death-1 ligand-1; RRM1, ribonucleotide reductase M1; SPARC, secreted protein acidic and rich in cysteine; TS, thymidylate synthase; TTF-1, thyroid transcription factor-1.

EdelmanMJWatsonDWangXEicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy–Cancer and Leukemia Group B Trial 30203J Clin Oncol200826684885518281656

 PubMedGoogle Scholar

SimsirAWeiXJYeeHMoreiraACangiarellaJDifferential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimensAm J Clin Pathol2004121335035715023039

 PubMedGoogle Scholar

HeYWZhaoMLYangXYZengJDengQHHeJXPrognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancerCancer Chemother Pharmacol201575486186725732635

 PubMedGoogle Scholar

SèvePLaiRDingKClass III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10Clin Cancer Res200713399499917289895

 PubMed Web of Science ®Google Scholar

HidalgoMPlazaCMusteanuMSPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT TrialClin Cancer Res201521214811481826169969

 PubMed Web of Science ®Google Scholar

BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456

 PubMed Web of Science ®Google Scholar